Global Blood Therapeutics (GBT:ASX) Annual Reports & Investor Relations Material

Overview

Global Blood Therapeutics is a biopharmaceutical company that focuses on developing treatments for underserved patient communities. Founded in 2011, the company's main goal is to transform the treatment and care of sickle cell disease, a lifelong inherited blood disorder. GBT has achieved this goal by introducing the first FDA-approved treatment, Oxbryta, which directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. The company is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. GBT's drug discovery teams are currently working on new targets to develop the next generation of treatments for SCD.

Frequently Asked Questions

What is Global Blood Therapeutics's ticker?

Global Blood Therapeutics's ticker is GBT

What exchange is Global Blood Therapeutics traded on?

The company's shares trade on the ASX stock exchange

Where are Global Blood Therapeutics's headquarters?

They are based in Brisbane, Queensland

How many employees does Global Blood Therapeutics have?

There are 501-1000 employees working at Global Blood Therapeutics

What is Global Blood Therapeutics's website?

It is gbt.com

What type of sector is Global Blood Therapeutics?

Global Blood Therapeutics is in the Technology sector

What type of industry is Global Blood Therapeutics?

Global Blood Therapeutics is in the Information Technology Services industry

Who are Global Blood Therapeutics's peers and competitors?

The following five companies are Global Blood Therapeutics's industry peers:

- Radware

- Dell

- Yojee Limited

- Unisys

- Priority